Cytarabine - CAS 147-94-4
Catalog number: 147-94-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C9H13N3O5
Molecular Weight:
243.22
COA:
Inquire
Targets:
Nucleoside Antimetabolite/Analog
Description:
Cytarabine (Cytosine arabinoside, AraC) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Purity:
>98%
MSDS:
Inquire
InChIKey:
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI:
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
Canonical SMILES:
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
1.The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.
Harrison JS1, Wang X2, Studzinski GP1. Oncotarget. 2016 Apr 26. doi: 10.18632/oncotarget.8998. [Epub ahead of print]
Acute Myeloid Leukemia (AML) has grave prognosis due to aggressive nature of the disease, the toxicity of standard treatment, and overall low cure rates. We recently showed that AML cells in established culture treated with Cytarabine (AraC) and a differentiation agent combination show enhancement of AraC cytotoxicity. Here we elucidate molecular changes which underlie this observation with focus on AML blasts in primary culture. The cells were treated with AraC at concentrations achievable in clinical settings, and followed by the addition of Doxercalciferol, a vitamin D2 derivative (D2), together with Carnosic acid (CA), a plant-derived antioxidant. Importantly, although AraC is also toxic to normal bone marrow cell population, the enhanced cell kill by D2/CA was limited to malignant blasts. This enhancement of cell death was associated with activation of the monocytic differentiation program as shown by molecular markers, and the increased expression of vitamin D receptor (VDR).
2.Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M, Corrales-Alfaro C, Gutiérrez-Hernández O, Díaz-Chavez J, Labardini-Méndez J, Vidal-Millán S, Herrera LA. Chemotherapy. 2016;61(6):313-318. Epub 2016 Apr 28.
BACKGROUND: Cytarabine (Ara-C) is the primary drug in different treatment schemas for acute myeloid leukemia (AML) and requires the human equilibrative nucleoside transporter (hENT1) to enter cells. The deoxycytidine kinase (dCK) enzyme limits its activation rate. Therefore, decreased expression levels of these genes may influence the response rate to this drug.
3.Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ1, Cwynarski K2, Pulczynski E3, Ponzoni M4, Deckert M5, Politi LS6, Torri V7, Fox CP8, Rosée PL9, Schorb E10, Ambrosetti A11, Roth A12, Hemmaway C13, Ferrari A14, Linton KM15, Rudà R16, Binder M17, Pukrop T18, Balzarotti M19, Fabbri A20, Johnson Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.
4.Oleic Acid Protects Against Oxidative Stress Exacerbated by Cytarabine and Doxorubicin in Rat Brain.
Guzmán DC, Brizuela NO, Herrera MO, Olguín HJ1, García EH, Peraza AV, Mejía GB. Anticancer Agents Med Chem. 2016 May 3. [Epub ahead of print]
AIM: The objective of this study was to analyze the effect of doxorubicin and cytarabine on biogenic amines and oxidative biomarkers in brain of rats treated with oleic acid.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Nucleoside Antimetabolite/Analog Products


CAS 3094-09-5 Doxifluridine

Doxifluridine
(CAS: 3094-09-5)

Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.

CAS 70-00-8 Trifluridine

Trifluridine
(CAS: 70-00-8)

Trifluorothymidine (TFT) and is an inhibitor of thymidine phosphorylase. TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis...

Forodesine hydrochloride
(CAS: 284490-13-7)

Forodesine hydrochloride is the hydrochloride salt of Forodesine. Forodesine, also called as BCX-1777 or Immucillin-H, is an orally bioavailable inhibior of mam...

CAS 69-74-9 Cytarabine hydrochloride

Cytarabine hydrochloride
(CAS: 69-74-9)

Cytarabine, an antimetabolite analogue of cytidine with a modified sugar moiety, is an antimetabolic agent and DNA synthesis inhibitor.

CAS 65-46-3 Cytidine

Cytidine
(CAS: 65-46-3)

Cytidine is a nucleoside molecule that is formed when cytosine is attached to a ribose ring, cytidine is a component of RNA.

CAS 122111-03-9 Gemcitabine Hydrochloride

Gemcitabine Hydrochloride
(CAS: 122111-03-9)

Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells.

CAS 865838-26-2 RX-3117

RX-3117
(CAS: 865838-26-2)

RX-3117, also known as TV-1360 and fluorocyclopentenylcytosine, is an orally available and potent DNA synthesis inhibitor with potential antineoplastic activity...

CAS 75607-67-9 Fludarabine Phosphate

Fludarabine Phosphate
(CAS: 75607-67-9)

Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

Chemical Structure

CAS 147-94-4 Cytarabine

Quick Inquiry

Verification code

Featured Items